A rapid and sensitive LC-MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodone
Biomed Chromatogr. 2024 Apr 8:e5874. doi: 10.1002/bmc.5874. Online ahead of print.ABSTRACTA sensitive and reliable LC-MS/MS method was developed and validated for the quantification of oxycodone and metabolites in human plasma. The method has a runtime of 6 min and a sensitivity of 0.1 μg/L for all analytes. Sample preparation consisted of protein precipitation. Separation was performed on a Kinetix biphenyl column (2.1 × 100 mm, 1.7 μm), using ammonium formate 5 mm in 0.1% aqueous formic acid and methanol LC-MS grade 100% in gradient elution at a flow rate of 0.4 ml/min. Detection was performed in multiple reaction mon...
Source: Biomedical Chromatography : BMC - April 8, 2024 Category: Biomedical Science Authors: Lotte M G Hulskotte Inge Wilbrink-Pijffers Maurits E L Arbouw Guillemette E Benoist Frank G A Jansman Inge R F van Berlo-van de Laar Source Type: research
A rapid and sensitive LC-MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodone
Biomed Chromatogr. 2024 Apr 8:e5874. doi: 10.1002/bmc.5874. Online ahead of print.ABSTRACTA sensitive and reliable LC-MS/MS method was developed and validated for the quantification of oxycodone and metabolites in human plasma. The method has a runtime of 6 min and a sensitivity of 0.1 μg/L for all analytes. Sample preparation consisted of protein precipitation. Separation was performed on a Kinetix biphenyl column (2.1 × 100 mm, 1.7 μm), using ammonium formate 5 mm in 0.1% aqueous formic acid and methanol LC-MS grade 100% in gradient elution at a flow rate of 0.4 ml/min. Detection was performed in multiple reaction mon...
Source: Biomedical Chromatography : BMC - April 8, 2024 Category: Biomedical Science Authors: Lotte M G Hulskotte Inge Wilbrink-Pijffers Maurits E L Arbouw Guillemette E Benoist Frank G A Jansman Inge R F van Berlo-van de Laar Source Type: research
A rapid and sensitive LC-MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodone
Biomed Chromatogr. 2024 Apr 8:e5874. doi: 10.1002/bmc.5874. Online ahead of print.ABSTRACTA sensitive and reliable LC-MS/MS method was developed and validated for the quantification of oxycodone and metabolites in human plasma. The method has a runtime of 6 min and a sensitivity of 0.1 μg/L for all analytes. Sample preparation consisted of protein precipitation. Separation was performed on a Kinetix biphenyl column (2.1 × 100 mm, 1.7 μm), using ammonium formate 5 mm in 0.1% aqueous formic acid and methanol LC-MS grade 100% in gradient elution at a flow rate of 0.4 ml/min. Detection was performed in multiple reaction mon...
Source: Biomedical Chromatography : BMC - April 8, 2024 Category: Biomedical Science Authors: Lotte M G Hulskotte Inge Wilbrink-Pijffers Maurits E L Arbouw Guillemette E Benoist Frank G A Jansman Inge R F van Berlo-van de Laar Source Type: research
Exploring the Impact of CYP2D6 and UGT2B7 Gene-Drug Interactions, and CYP-mediated DDI on Oxycodone and Oxymorphone Pharmacokinetics using Physiologically-Based Pharmacokinetic Modelling and Simulation
Eur J Pharm Sci. 2024 Jan 1:106689. doi: 10.1016/j.ejps.2023.106689. Online ahead of print.ABSTRACTOxycodone is one of the most commonly used opioids to treat moderate to severe pain. It is metabolized mainly by CYP3A4 and CYP2D6, while only a small fraction of the dose is excreted unchanged into the urine. Oxymorphone, the metabolite primarily formed by CYP2D6, has a 40- to 60-fold higher mu-opioid receptor affinity than the parent compound. While CYP2D6-mediated gene-drug-interactions (GDIs) and drug-drug interactions (DDIs) are well-studied, they only account for a portion of the variability in oxycodone and oxymorphone...
Source: European Journal of Pharmaceutical Sciences - January 3, 2024 Category: Drugs & Pharmacology Authors: Marian Klose Rodrigo Cristofoletti Carolina de Miranda Silva Naveen Mangal Jacques Turgeon Veronique Michaud Lawrence J Lesko Stephan Schmidt Source Type: research
Strain and sex-related behavioral variability of oxycodone dependence in rats
In conclusion, this study identifies strain differences in the behavioral responses and pharmacokinetics associated with oxycodone self-administration in rats, providing a robust foundation for identifying genetic and molecular variants associated with various facets of the opioid addiction process.PMID:37327971 | DOI:10.1016/j.neuropharm.2023.109635 (Source: Neuropharmacology)
Source: Neuropharmacology - June 16, 2023 Category: Drugs & Pharmacology Authors: Michelle R Doyle Angelica R Martinez Ran Qiao Selen Dirik Francesca Di Ottavio Glenn Pascasio R émi Martin-Fardon Christopher Benner Olivier George Francesca Telese Giordano de Guglielmo Source Type: research
Strain and sex-related behavioral variability of oxycodone dependence in rats
In conclusion, this study identifies strain differences in the behavioral responses and pharmacokinetics associated with oxycodone self-administration in rats, providing a robust foundation for identifying genetic and molecular variants associated with various facets of the opioid addiction process.PMID:37327971 | DOI:10.1016/j.neuropharm.2023.109635 (Source: Neuropharmacology)
Source: Neuropharmacology - June 16, 2023 Category: Drugs & Pharmacology Authors: Michelle R Doyle Angelica R Martinez Ran Qiao Selen Dirik Francesca Di Ottavio Glenn Pascasio R émi Martin-Fardon Christopher Benner Olivier George Francesca Telese Giordano de Guglielmo Source Type: research
Strain and sex-related behavioral variability of oxycodone dependence in rats
In conclusion, this study identifies strain differences in the behavioral responses and pharmacokinetics associated with oxycodone self-administration in rats, providing a robust foundation for identifying genetic and molecular variants associated with various facets of the opioid addiction process.PMID:37327971 | DOI:10.1016/j.neuropharm.2023.109635 (Source: Neuropharmacology)
Source: Neuropharmacology - June 16, 2023 Category: Drugs & Pharmacology Authors: Michelle R Doyle Angelica R Martinez Ran Qiao Selen Dirik Francesca Di Ottavio Glenn Pascasio R émi Martin-Fardon Christopher Benner Olivier George Francesca Telese Giordano de Guglielmo Source Type: research
Strain and sex-related behavioral variability of oxycodone dependence in rats
In conclusion, this study identifies strain differences in the behavioral responses and pharmacokinetics associated with oxycodone self-administration in rats, providing a robust foundation for identifying genetic and molecular variants associated with various facets of the opioid addiction process.PMID:37327971 | DOI:10.1016/j.neuropharm.2023.109635 (Source: Neuropharmacology)
Source: Neuropharmacology - June 16, 2023 Category: Drugs & Pharmacology Authors: Michelle R Doyle Angelica R Martinez Ran Qiao Selen Dirik Francesca Di Ottavio Glenn Pascasio R émi Martin-Fardon Christopher Benner Olivier George Francesca Telese Giordano de Guglielmo Source Type: research
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
CONCLUSION: Co-administration of enzalutamide significantly reduced exposure to oxycodone and its active metabolite oxymorphone in men with prostate cancer. This should be taken into account when prescribing enzalutamide combined with oxycodone.PMID:37162620 | DOI:10.1007/s40262-023-01255-1 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 10, 2023 Category: Cancer & Oncology Authors: S E H Detert Oude Weme L M G Hulskotte W L Vervenne A L T Imholz R G H M Cremers K Taxis A K L Reyners I R F van Berlo-van de Laar F G A Jansman G E Benoist Source Type: research
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
CONCLUSION: Co-administration of enzalutamide significantly reduced exposure to oxycodone and its active metabolite oxymorphone in men with prostate cancer. This should be taken into account when prescribing enzalutamide combined with oxycodone.PMID:37162620 | DOI:10.1007/s40262-023-01255-1 (Source: Cancer Control)
Source: Cancer Control - May 10, 2023 Category: Cancer & Oncology Authors: S E H Detert Oude Weme L M G Hulskotte W L Vervenne A L T Imholz R G H M Cremers K Taxis A K L Reyners I R F van Berlo-van de Laar F G A Jansman G E Benoist Source Type: research
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
CONCLUSION: Co-administration of enzalutamide significantly reduced exposure to oxycodone and its active metabolite oxymorphone in men with prostate cancer. This should be taken into account when prescribing enzalutamide combined with oxycodone.PMID:37162620 | DOI:10.1007/s40262-023-01255-1 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 10, 2023 Category: Cancer & Oncology Authors: S E H Detert Oude Weme L M G Hulskotte W L Vervenne A L T Imholz R G H M Cremers K Taxis A K L Reyners I R F van Berlo-van de Laar F G A Jansman G E Benoist Source Type: research
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
ConclusionCo-administration of enzalutamide significantly reduced exposure to oxycodone and its active metabolite oxymorphone in men with prostate cancer. This should be taken into account when prescribing enzalutamide combined with oxycodone. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - May 10, 2023 Category: Drugs & Pharmacology Source Type: research
Variation in adverse drug events of opioids in the United States
Conclusion: The use of the FAERS with the ARCOS provides insights into dynamic changes in ADEs of the selected opioids in the US. There is further need to monitor and address the ADEs of these drugs. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - March 24, 2023 Category: Drugs & Pharmacology Source Type: research
A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
ConclusionsDrugs employing ADF technology may reduce the likelihood of tampering when compared to non-ADF formulations in a treatment-center population, which represents an opportunity for intervention in OUD among those still requiring pain management. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 1, 2023 Category: Drugs & Pharmacology Source Type: research
